Introduction Despite the importance of clinical trial participation among cancer patients, few
participate—and even fewer patients from ethnic and racial minoritized groups. It is unclear …

Background The intersection of race and older age compounds existing health disparities
experienced by historically marginalised communities. Therefore, racialised older adults …

Background Black breast and ovarian cancer patients are underrepresented in clinical
cancer trials disproportionate to the prevalence of these cancers in Black females …

PURPOSE Patients with cancer from racial and ethnic minorities, referred to as culturally
and linguistically diverse (CALD) in Australia, are significantly under-represented in cancer …

Background Clinical trials are an essential part of advancing care for cancer patients.
Historically, however, racial minorities and females have been underrepresented in these …

Background: Large population-based registries, such as the Surveillance, Epidemiology and
End Results (SEER) Registry, help in the study of rare tumors, including medullary thyroid …

Background Recruitment of cancer clinical trial (CCT) participants, especially participants
representing the diversity of the US population, is necessary to create successful …

Health care systems and providers have a responsibility to ensure that access to cancer
clinical trials, opportunities to complete the trial, and access to lifelong survivor care are all …

Introduction Prior studies investigating the racial and ethnic representation of orthopedic trial
participants have found low rates of reporting, but these studies are dated due to the passing …

Abstract Purpose of Review Cancer clinical trials remain highly underrepresented from
racial and ethnic minorities. The lack of diversity in clinical trials significantly impacts the …